Finance

Lists
NAV:CVE
Navco Pharmaceuticals Inc
CA$0,0050
0,00%
(0,00) 1D
28 āš•.āšĨ., 13 āŧ‚āšĄāš‡ 31 āš™āšēāš—āšĩ 29 āš§āšīāš™āšēāš—āšĩ GMT-5  ·   CAD
All symbols
SymbolPriceChange% Change
Generating top insights for NAV...
Mkt. cap
285,35 āšžāšąāš™
Avg. vol.
773,00
Volume
0,00
52-wk high
CA$0,01
52-wk low
CA$0,00
EPS
CA$-0,00
Beta
14,27
Shares outstanding
57,07 āšĨāŧ‰āšēāš™
Mkt. cap
285,35 āšžāšąāš™
Avg. vol.
773,00
Volume
0,00
52-wk high
CA$0,01
52-wk low
CA$0,00
EPS
CA$-0,00
Beta
14,27
Shares outstanding
57,07 āšĨāŧ‰āšēāš™
News stories
From web sources and news partners
Euronews.com
Euronews.com
·
7 āš™āšēāš—āšĩāšāŧˆāš­āš™
Markets fluctuate as US rate worries temper tech bounce
FOREX.com
FOREX.com
·
1 āšŠāšŧāŧˆāš§āŧ‚āšĄāš‡āšāŧˆāš­āš™
Nasdaq 100 Outlook: Slingshot rally or false dawn?
Yahoo Finance
Yahoo Finance
·
2 āšŠāšŧāŧˆāš§āŧ‚āšĄāš‡āšāŧˆāš­āš™
Dow, S&P 500, Nasdaq Futures Edge Higher After Red-Hot Inflation Data And Nvidia Losses: CRWV, TTWO, NLST, NBIS In Focus
Seeking Alpha
Seeking Alpha
·
1 āšŠāšŧāŧˆāš§āŧ‚āšĄāš‡āšāŧˆāš­āš™
Anthropic opens Australian retail IPO as demand builds ahead of Nasdaq debut (ANT:Pending)
About Navco Pharmaceuticals Inc
CEO-
Employees-
Founded-
Headquartersāŧāš§āš™āš„āšđāŧ€āš§āšĩ, āššāšĢāšīāš—āšīāšŠ āŧ‚āš„āšĨāšģāŧ€āššāš, āŧāš„āš™āšēāš”āšē
SectorHealth Care
IndustryBiotechnology
Websitenavcopharma.com
Previous reportsAll values in CAD
Loading Previous Earnings...
Revenue
Net income
All values in CAD
āš.āš. 2025
āš—.āš§. 2025
āšĄ.āš™. 2026
āšĄāšī.āš–. 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
34,77 āšžāšąāš™
2,06 āšžāšąāš™
2,95 āšžāšąāš™
1,58 āšžāšąāš™
Operating expense
34,77 āšžāšąāš™
2,06 āšžāšąāš™
2,95 āšžāšąāš™
1,58 āšžāšąāš™
Total operating expenses
34,77 āšžāšąāš™
2,06 āšžāšąāš™
2,95 āšžāšąāš™
1,58 āšžāšąāš™
Operating income
-34,77 āšžāšąāš™
-2,06 āšžāšąāš™
-2,95 āšžāšąāš™
-1,58 āšžāšąāš™
Other non operating income
-2,27 āšžāšąāš™
-1,16 āšžāšąāš™
-10,54 āšžāšąāš™
-1,91 āšžāšąāš™
EBT including unusual items
-39,64 āšžāšąāš™
-5,83 āšžāšąāš™
-16,55 āšžāšąāš™
-6,82 āšžāšąāš™
EBT excluding unusual items
-39,64 āšžāšąāš™
-5,83 āšžāšąāš™
-16,55 āšžāšąāš™
-6,82 āšžāšąāš™
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-39,64 āšžāšąāš™
-5,83 āšžāšąāš™
-16,55 āšžāšąāš™
-6,82 āšžāšąāš™
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
-
Interest expense
-2,61 āšžāšąāš™
-2,61 āšžāšąāš™
-3,06 āšžāšąāš™
-3,33 āšžāšąāš™
Net interest expenses
-2,61 āšžāšąāš™
-2,61 āšžāšąāš™
-3,06 āšžāšąāš™
-3,33 āšžāšąāš™
Depreciation and amortization charges
-
-
-
-
EBITDA
-26,38 āšžāšąāš™
-
-
-
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
āŧāš­āšąāššāš‚āš­āš‡ Google